Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping

Detalhes bibliográficos
Autor(a) principal: Freitas, Miguel Alexandre Guerreiro Marques
Data de Publicação: 2022
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/163998
Resumo: To better comprehend who can benefact from the value of an innovation, the entrepreneur should acquire knowledge about the topic, as well as identifying all potential partners in a value chain, to obtain valuable insights and progress faster. Xaniglucan is the first product from Deca Pharmaceuticals, aimed to cure resistant C. glabrata infections. Leveraging on the product’s characteristics and by relying on IP protection, the team can hope to validate assumptions with the stakeholders identified to develop the drug into later stages of clinical trials. The entrepreneur now understands who plays a key role in different stages of development.
id RCAP_27a30053a762c66e8b5750571e6338a6
oai_identifier_str oai:run.unl.pt:10362/163998
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mappingInnovationPatentStakeholderInvasive fungal infectionC. glabrataPharmaceutical companyR&DCaffeineNickelMode of actionOrganometallic chemistryEsgDomínio/Área Científica::Ciências Sociais::Economia e GestãoTo better comprehend who can benefact from the value of an innovation, the entrepreneur should acquire knowledge about the topic, as well as identifying all potential partners in a value chain, to obtain valuable insights and progress faster. Xaniglucan is the first product from Deca Pharmaceuticals, aimed to cure resistant C. glabrata infections. Leveraging on the product’s characteristics and by relying on IP protection, the team can hope to validate assumptions with the stakeholders identified to develop the drug into later stages of clinical trials. The entrepreneur now understands who plays a key role in different stages of development.Arantes-Oliveira, Nuno Manuel de Castro SantosRUNFreitas, Miguel Alexandre Guerreiro Marques2024-02-23T09:19:41Z2023-01-202022-12-162023-01-20T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/10362/163998TID:203315367enginfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:50:10Zoai:run.unl.pt:10362/163998Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:59:59.175160Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
title Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
spellingShingle Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
Freitas, Miguel Alexandre Guerreiro Marques
Innovation
Patent
Stakeholder
Invasive fungal infection
C. glabrata
Pharmaceutical company
R&D
Caffeine
Nickel
Mode of action
Organometallic chemistry
Esg
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
title_short Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
title_full Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
title_fullStr Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
title_full_unstemmed Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
title_sort Deca pharmaceuticals: fighting fungal infections with organometallic compounds, Iinnovation´s overview and ecosystem mapping
author Freitas, Miguel Alexandre Guerreiro Marques
author_facet Freitas, Miguel Alexandre Guerreiro Marques
author_role author
dc.contributor.none.fl_str_mv Arantes-Oliveira, Nuno Manuel de Castro Santos
RUN
dc.contributor.author.fl_str_mv Freitas, Miguel Alexandre Guerreiro Marques
dc.subject.por.fl_str_mv Innovation
Patent
Stakeholder
Invasive fungal infection
C. glabrata
Pharmaceutical company
R&D
Caffeine
Nickel
Mode of action
Organometallic chemistry
Esg
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
topic Innovation
Patent
Stakeholder
Invasive fungal infection
C. glabrata
Pharmaceutical company
R&D
Caffeine
Nickel
Mode of action
Organometallic chemistry
Esg
Domínio/Área Científica::Ciências Sociais::Economia e Gestão
description To better comprehend who can benefact from the value of an innovation, the entrepreneur should acquire knowledge about the topic, as well as identifying all potential partners in a value chain, to obtain valuable insights and progress faster. Xaniglucan is the first product from Deca Pharmaceuticals, aimed to cure resistant C. glabrata infections. Leveraging on the product’s characteristics and by relying on IP protection, the team can hope to validate assumptions with the stakeholders identified to develop the drug into later stages of clinical trials. The entrepreneur now understands who plays a key role in different stages of development.
publishDate 2022
dc.date.none.fl_str_mv 2022-12-16
2023-01-20
2023-01-20T00:00:00Z
2024-02-23T09:19:41Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/163998
TID:203315367
url http://hdl.handle.net/10362/163998
identifier_str_mv TID:203315367
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138176390922240

Registros relacionados